Aerospace Surges, Profit Collapses Unexplained—the Credibility Gap
The quarter delivered 40% aerospace growth and a ₹5,960 crore order book, but consolidated profit fell 99% YoY with no explanation. EBITDA grew 14%; profit imploded. Management didn't address the gap.
₹30.9 Cr
-99.4% YoY
+14% YoY
₹100 Cr at 15.9% margin
₹123 Cr
+40% YoY (beat 25% guidance)
₹5,960 Cr
Up from ₹2,350 Cr (5-yr)
Raymond delivered a tactically blowout aerospace quarter—40% growth, ₹5,960 crore order book, ₹1,632 crore live RFQ pipeline. The market bought it, posting a +1.96% rally on day 1 of the result announcement. But look deeper, and there's a credibility breach: consolidated PAT crashed 99.4% to ₹30.9 crore (NPM 4.9%), while EBITDA climbed 14%. That gap—where revenue and EBITDA grow but profit collapses—is the real quarter. And management didn't explain it.
The PAT-EBITDA divergence: where did ₹480 crore in profit go?
Revenue rose 15.5% YoY to ₹605.6 crore. EBITDA rose 14% (management: ₹100 crore at 15.9% margin). But net profit fell to ₹30.9 crore from an implied prior-year level of ~₹510 crore. The gap is ~₹480 crore—an 99% cliff. Management did not flag any one-time charge on the call. R&D is fully expensed to support 40% aerospace growth (management notes this will normalize as programs mature), but that is an ongoing operational cost, not a one-time item. The absence of an explanation for a 99% profit decline, despite EBITDA growth, is a material credibility risk. Either (1) prior year had an inflated profit that is now normalizing; (2) Q1 FY27 harbors unspoken cost shocks or customer mix deterioration; or (3) taxes, depreciation, or finance costs spiked. Until clarified, the order book story masks an earnings quality issue.
As these newly developed programs transition into steady-state production, EBITDA margins will stabilize.
Total income ₹628 Cr, 13% YoY growth
Delivered ₹605.6 Cr, 15.5% YoY (₹22.4 Cr discrepancy vs call)
Contradicted
Aerospace 40% growth, 25% EBITDA growth
Aerospace ₹123 Cr (+40%), EBITDA ₹26 Cr (21.2% margin, down from 23.7% YoY; R&D fully expensed)
Supported (growth yes; margin compression material)
Precision auto 46% EBITDA growth on operating leverage
Precision auto ₹444 Cr (+11%), EBITDA ₹61 Cr (13.8% margin, up from 10.6%). Export ramp-up confirmed.
Supported
No meaningful supply chain risk exposure
Q&A later admits logistics, tool/carbide, wage cost inflation. Mitigation via efficiency and customer pass-through not quantified.
Overstated
Market demand far exceeds supply; execution is the constraint
RFQ pipeline ₹1,632 Cr and 10-yr order book ₹5,960 Cr support this. But RFQ-to-order conversion timing and customer diversification (40–45% top 3) unproven.
Supported (with execution caveat)
Margins will stabilize and improve
Aerospace EBITDA margin fell from 23.7% to 21.2% YoY. Cost headwinds ongoing; pricing power effectiveness unproven.
Aspirational, not guaranteed
What changed on this call
Order book horizon extended from 5-year to 10-year (₹5,960 Cr vs prior ₹2,350 Cr 5-yr)
Aerospace margin temporarily compressed to 21.2% due to R&D acceleration; normalization timing not specified
Aftermarket automotive product line launching Q2 FY27 (new revenue lever; contribution size unknown)
Defence segment strategy in development (ex-BEL CXO hired); color deferred to next quarter
Medical device certification just received (new vertical; pipeline unknown; color deferred)
Capex plan (₹1,000 Cr, ₹510 Cr aerospace, ₹430 Cr auto) and greenfield timeline (late 2027) reaffirmed
How the street is positioned
The stock rallied +1.96% on day 1 of the result (from ₹614.95 pre-announcement close), with 39.9% delivery volume; by day 3, the pop had moderated to +0.65%. The market chose to buy the aerospace narrative (40% growth, extended order book, UK FTA tailwind) and overlook the PAT collapse. Classic sell-the-profit-miss-buy-the-order-book optics. Yet institutional positioning reveals caution: FII ownership fell 1.86 percentage points QoQ (from 9.75% to 7.89%), a sell-on-good-news signal despite bullish call tone. The stock is trading at ₹642 as of mid-August, just 0.53% below its all-time high of ₹645.4. All key moving averages (SMA20 ₹606.96, SMA50 ₹595.03, SMA200 ₹480.5) are below the current price; RSI is at 67.7 (neutral, not yet overbought). Risk/reward is skewed to the downside—the stock has rallied 100% off its 52-week low (₹320.55) and sits at the ceiling of its range. There is no margin of safety for a holder concerned about profit credibility.
The bull-bear ledger
Aerospace in a structural up-cycle; global OEM build rates stabilizing at higher target production
10-year order book ₹5,960 Cr and RFQ pipeline ₹1,632 Cr provide concrete decade-long revenue runway
UK-India FTA and US tariff clarity are multiyear tailwinds; China Plus One reallocation benefits all Indian suppliers
22-year aerospace headstart, build-to-spec design certification, 25+ OEMs, and approved-source moat create formidable barriers to entry
Precision auto segment executing: +11% revenue, +46% EBITDA growth from export ramp and operating leverage
Net cash ₹129 Cr and zero debt provide capex flexibility for ₹1,000 Cr greenfield plan
PAT crashed 99% YoY with zero explanation on call; breach of earnings credibility and transparency
Aerospace EBITDA margin fell to 21.2% from 23.7% YoY; cost headwinds (logistics, tools, wages) unquantified and pricing mitigation informal
Greenfield approval lag (6 months) shifts upside to FY28; existing facility ceiling ₹600 Cr limits near-term growth
Customer concentration 40–45% with top 3 OEMs; diversification to 8–10 customers is aspirational, execution-dependent
FII trimmed 1.86pp despite bullish aerospace optics; institutional skepticism on profit quality
Stock at all-time high with no margin of safety; price above all key moving averages limits upside room
Risks, ranked by what should concern a holder
PAT credibility and earnings quality
HighProfit fell 99% YoY while EBITDA grew 14%. If structural (customer mix deterioration, cost shock, prior-year base reset), 25% aerospace growth will not translate to shareholder returns. If one-time, Q2 recovery is critical. Lack of management transparency is a red flag.
Cost inflation mitigation unproven
HighLogistics, tool/carbide, HSS, and wage costs are up. Management claims efficiency and customer pass-through, but magnitude and timeline unspecified. If price realization lags, margin targets (Aerospace 25%, Precision auto 12–13%) are at risk.
Greenfield execution and approval lag
MediumCommercial production late 2027 with 6-month approval lag. FY28 is the realistic ramp start. Current facility ceiling ~₹600 Cr limits organic growth until then. Regulatory delays could push upside further out.
Customer concentration and RFQ conversion
MediumTop 3 OEMs represent 40–45% of order book. Diversification depends on ₹1,632 Cr RFQ-to-order conversion. If win rates slip or new customer ramp stalls, concentration risk persists and customer loss becomes more material.
Institutional positioning deteriorating
MediumFII trimmed 1.86pp QoQ (from 9.75% to 7.89%) despite bullish call optics. Sell-on-good-news signal suggests institutional doubt. If FII selling accelerates, price support weakens.
Valuation at all-time high with limited margin of safety
MediumStock at ₹642, 0.53% below ATH ₹645.4, up 100% off 52-week low. A disappointment on Q2 PAT or margin guidance could trigger sharp correction.
The debate
1 · Q2 FY27 PAT recovery (most critical metric)
If NPM rebounds to 8–9% and PAT exceeds ₹50 Cr, Q1 collapse was one-time and credibility recovers. If PAT stays at 4.9% or worsens, something is structurally broken. This single metric will determine whether the aerospace growth story translates to shareholder returns.
2 · Cost inflation quantification and pricing power evidence
Management must disclose magnitude of logistics/tool/wage pressures and show Q2 gross or EBITDA margin trends that prove efficiency + price pass-through are working. This determines path to target margins (Aerospace 25%, Precision auto 12–13%).
3 · Greenfield approval milestones and RFQ-to-order conversion
Track regulatory/customer approvals for Andhra Pradesh facility; delays signal execution risk. Monitor ₹1,632 Cr pipeline conversion rates and new customer wins—proof of diversification from top-3 OEM concentration (currently 40–45%).
4 · Aftermarket rollout traction and defence strategy reveal
Q2 aftermarket launch contribution and Q2–Q3 defence segment strategy detail are upside catalysts if credible. Size these relative to aerospace/auto to assess diversification upside.
Raymond delivered a tactically strong quarter on aerospace (40% growth, ₹5,960 Cr order book) but a strategically weak one on profit credibility. The market rewarded the narrative (+1.96% day 1) and absorbed the order book story. But the 99% PAT collapse, unexplained on the call and unaddressed in management commentary, is the real earnings story. Until management reconciles that gap—either by proving Q1 is one-time or transparently explaining structural margin compression—the bull case remains a story about volumes, not profits.
For a holder, the single number to track is Q2 PAT. If it rebounds to a reasonable NPM (8–9%), the aerospace thesis holds and the stock can justify near-ATH valuations with cautious confidence. If PAT stays depressed, the order book and capex become footnotes in a profit-quality miss, and the stock deserves a lower multiple.
Verdict: Hold. Aerospace tailwinds are real and multiyear, but execution risk is high and valuation is at the peak of the range. Accumulate on any correction below ₹600; hold existing positions above ₹600 until Q2 PAT clarifies the profit-quality debate.
Informational and educational content only. Not investment advice.